Home > Cardiology > ESC 2022 > Conservative or invasive management for high-risk kidney disease patients with ischaemia?

Conservative or invasive management for high-risk kidney disease patients with ischaemia?

Presented By
Prof. Sripal Bangalore, New York University School of Medicine, NY, USA
Conference
ESC 2022
Trial
Phase 4, ISCHEMIA-CKD
An invasive strategy for treating ischaemia in patients with chronic kidney disease (CKD) and chronic coronary disease was not superior to conservative management regarding the reduction of deaths after 5 years, according to the late-breaking results of the ISCHEMIA-CKD EXTEND trial [1]. To date, it has not been thoroughly investigated whether a conservative or invasive strategy is the optimal management for patients with CKD and chronic coronary disease. To address this issue, the ISCHEMIA-CKD trial (NCT01985360) included 777 patients with CKD and moderate-to-severe ischaemia. Participants were randomised to an initial invasive strategy for treating ischaemia, consisting out of cardiac catheterisation and optimal revascularisation, either with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), plus guideline-direct...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on